Back to results
US 2013/0296279 A1Published application
Substituted tetracyclines
AssigneeConcert Pharmaceutcals Inc.
InventorAdam Morgan
Life of this patent
Estimating the term…
Abstract
The invention in one embodiment is directed to a compound of formula (I) or a pharmaceutically acceptable salt thereof. The invention is also directed to a composition comprising the compound of formula I or a pharmaceutically acceptable salt, and methods of treating the indications listed herein.
Claims20
A compound of Formula I:
- or a pharmaceutically acceptable salt thereof, wherein:
- V is CH or N;
- W is F;
- each X is independently selected from H and D;
- each Y is independently selected from CH3 and CD3;
- Z is H;
- NH2;
- C1-C6 alkylene-R1 wherein the C1-C6 alkylene is optionally substituted with deuterium;
- or NHQR1;
- Q is —C(O)— or a direct bond;
- R1 is C0-C6 alkyl optionally substituted with deuterium and optionally substituted with R4;
- or NH(C1-C6 alkyl) wherein the C1-C6 alkyl is optionally substituted with deuterium;
- R4 is NR2R3;
- or a 3- to 10-membered heterocyclyl containing at least one ring nitrogen wherein the 3- to 10-membered heterocyclyl is optionally substituted with deuterium at a carbon atom and is optionally substituted with C1-C6 alkyl that is optionally substituted with deuterium;
- each of R2 and R3 is independently H;
- C1-C6 alkyl;
- (C3-C8 cycloalkyl);
- or (C0-C2)alkylene(C3-C8 cycloalkyl);
- wherein each C1-C6 alkyl, (C3-C8 cycloalkyl), and (C0-C2)alkylene(C3-C8 cycloalkyl) of R2 and R3 is independently optionally substituted with deuterium;
- with the proviso that if W is other than CD3, OCD3 or N(CD3)2;
- each X is H;
- and each Y is CH3;
- then Z comprises deuterium;
- and with the proviso that if W is N(CH3)2 or N(CD3)2, then X5 is D and at least one of X1a, X1b, X2a, X2b, X3 and X4 is hydrogen.
21 more elements
Dependencies are inferred from the claim text.